Evommune, Inc./$EVMN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
- Ticker
- $EVMN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 48
- Headquarters
- Palo Alto, United States
- Website
- www.evommune.com
Evommune, Inc. Metrics
BasicAdvanced
$241M
-
-$4.15
-
-
Price and volume
Market cap
$241M
52-week high
$33.20
52-week low
$4.94
Average daily volume
963K
Financial strength
Current ratio
11.68
Quick ratio
11.482
Long term debt to equity
0.025
Total debt to equity
0.031
Profitability
EBITDA (TTM)
-100.356
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-946.68%
Operating margin (TTM)
-1,018.94%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-31.99%
Return on equity (TTM)
-52.11%
Valuation
Price to revenue (TTM)
15.177
Price to book
0.87
Price to tangible book (TTM)
0.87
Price to free cash flow (TTM)
-2.033
Free cash flow yield (TTM)
-49.19%
Free cash flow per share (TTM)
-3.271
Growth
Revenue change (TTM)
233.33%
Earnings per share change (TTM)
-90.41%
What the Analysts think about Evommune, Inc.
Analyst ratings (Buy, Hold, Sell) for Evommune, Inc. stock.
Analyst projections of the future price of Evommune, Inc. stock.
Evommune, Inc. Financial Performance
Revenues and expenses
Evommune, Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evommune, Inc. News
AllArticlesVideos
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
MarketBeat3 hours ago
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Business Wire2 days ago
Evommune Announces $30 Million Private Placement
Business Wire2 days ago
Funds containing Evommune, Inc.
Fund name | Fund size | $EVMN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.